OrbiMed Asia Backs Iswarya Fertility Center With $37 Million Growth Investment

OrbiMed Asia, a global healthcare-focused investment firm, has invested roughly $37 million, about Rs 350 crore, in Chennai-based Iswarya Fertility Center. The company says the round ranks among the largest growth investments made in India’s IVF industry so far.

Iswarya operates over 85 fertility centres across eight states, and the new capital will go toward expanding that network into underserved regions, upgrading clinical infrastructure, and investing in digital tools for patients and clinicians alike. The company also plans to grow its embryology talent pipeline as part of the expansion.

‘Our focus over the next phase is to deepen our pan-India presence, enter underserved geographies and keep raising the bar on clinical outcomes,’ said managing director Arun Muthuvel. ‘We will invest in our people, technology and patient experience.’

The transaction was advised by Veda Corporate Advisors, whose managing director, VP Rajan, said it ‘drew strong interest from marquee investors’ — a sign that institutional capital continues to flow into India’s fertility and reproductive healthcare sector even as broader dealmaking has cooled in other segments.

With this round, Iswarya joins a small group of Indian fertility chains that have secured large-ticket growth capital in recent years, underlining investor confidence in the category’s long-term demand curve.